Status:
NOT_YET_RECRUITING
Seravue Validation Study for Hepatocellular Carcinoma (HCC) Diagnosis
Lead Sponsor:
ImCare Biotech
Conditions:
Hepatic Cancer
Eligibility:
All Genders
21-84 years
Brief Summary
Currently, ultrasound with or without AFP is the standard of care when it comes to surveillance for HCC in high-risk populations. While ultrasound is non-invasive and plays a critical role in detectin...
Detailed Description
Patients who meet eligibility criteria and provide written informed consent will undergo comprehensive screening evaluations and standard of care clinical laboratory tests, including hepatic ultrasoun...
Eligibility Criteria
Inclusion
- INCLUSION/EXCLUSION CRITERIA:
- Patients who provide written informed consent and meet eligibility criteria will undergo baseline assessments and be entered into the study.
- Inclusion Criteria:
- A patient must meet all of the following criteria to be eligible for this study:
- The patient is willing and able to provide signed informed consent.
- The patient is aged ≥21to ≤84 years.
- The patient is willing to undergo phlebotomy and provide blood samples for future biomarker analysis.
- The patient is willing and able to undergo regularly scheduled onsite liver cancer surveillance by ultrasound and AFP and any resulting axial imaging such as computed tomography (CT, with or without contrast), magnetic resonance imaging (MRI), or ultrasound per the standard of care guidelines and study protocol schedule.
- The patient has been diagnosed with hepatic cirrhosis of any etiology (both viral and non-viral), or Hepatitis B Virus (HBV). This includes HBV patients with pre-existing cirrhosis prior to antiviral therapy or other treatments leading to fibrosis regression who continue to be at risk.
- a. Cirrhosis may be diagnosed by any one of the following three methods: i. Biopsy and histological examination ii. Fibroscan (VCTE ≥ 12.5kPa) for all etiologies except HBV), Magnetic resonance elastography (≥ 4 kPa) iii. A combination of imaging (MRI, CT, or ultrasound) demonstrating a cirrhotic appearing liver AND at least one of the following:
- 1\. Thrombocytopenia 2. Clinical symptoms (including but not limited to ascites, portal hypertension, hypersplenism, esophageal varices, and encephalopathy).
- 6\) The patient has been diagnosed with HBV without cirrhosis.
- HBV will be defined by either a positive blood test for HBsAg, quantitative HBsAg, HBeAg OR detectable HBV DNA prior to initiating antiviral therapy.
- Patients are:
- i. Asian males ≥ 40 years old OR ii. Asian females ≥ 50 years old OR iii. Patients of any ethnicity with a page B score ≥ 10
- Exclusion Criteria
- A patient who meets any of the following criteria will be excluded from this study:
- Any health condition or other reason which, in the opinion of the investigator, would prelude study participation.
- Current Child Pugh C cirrhosis
- The patient has previously been diagnosed with a primary liver cancer or any cancer that has metastasized.
- The patient has participated in an interventional clinical study within 30 days prior to screening in which an experimental treatment was administered.
- The patient is unable or unwilling to submit to phlebotomy for testing or undergo ultrasound or other diagnostic imaging such as contrast-enhanced CT or MRI as recommended by AASLD standard of care guidelines.
- The patient would not routinely be recommended for HCC surveillance.
- The female patient is pregnant or plans to become pregnant during the study.
- History of solid nodule on baseline ultrasound (i.e., lesion 1cm or greater) within 9 months prior to consent without subsequent diagnostic multi-phase CT/MRI demonstrating benign nature
- AFP \>20 ng/mL within 6 months prior to consent, in the absence of a contrast-enhanced multi-phase CT or MRI (before or after) in the past year demonstrating lack of suspicious liver lesions.
- a. If the AFP is \>20 ng/mL during the study, the patient should undergo a contrast-enhanced multi-phase CT or MRI. if the patient has consistent elevations that are not increasing, repeat diagnostic testing will be left to the discretion of the investigator or the faculty.
- History of LR-4, LR-5, or LR-M on multi-phase CT or contrast-enhanced MRI prior to consent
- Patient's provider is planning to use only MRI- or CT- based surveillance moving forward
- History of Fontan associated liver disease or cardiac cirrhosis
- Actively listed for liver transplantation
Exclusion
Key Trial Info
Start Date :
August 1 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 1 2029
Estimated Enrollment :
1392 Patients enrolled
Trial Details
Trial ID
NCT06994130
Start Date
August 1 2025
End Date
August 1 2029
Last Update
June 4 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States, 02215